Veno-occlusive disease in pediatric patients affected by Wilms tumor.


BACKGROUND Hepatic veno-occlusive disease (VOD) is a rare and potentially severe complication of chemotherapy. We describe five patients who developed VOD after chemotherapy for Wilms tumor (WT) and evaluate the role of plasminogen activator inhibitor-1 (PAI-1) and defibrotide for diagnosis and therapy of VOD, respectively. PATIENTS AND METHODS Thirty-five patients treated from 2002 to 2009 for WT were eligible. Diagnosis of VOD was according McDonald's criteria that required two of the following: jaundice, hepatomegaly and/or right upper quadrant pain, weight gain with or without ascites. RESULTS VOD occurred in 5 of 35 patients (14%) after 21-105 days from starting chemotherapy. Two patients developed multiorgan failure (MOF). PAI-1 was high in four patients who were tested. Three patients were treated with defibrotide and no side effects were reported while two patients received supportive measures only. Four patients recovered and three of them received defibrotide. They are all alive and well after a median follow-up of 35 months. One of two patients not treated with defibrotide died of MOF. CONCLUSIONS PAI-1 levels were abnormal in WT-VOD. Defibrotide was a safe, well-tolerated, and potentially efficacious therapy in this group of patients. Further prospective study is needed in WT-VOD to confirm these data.

DOI: 10.1002/pbc.22841
Citations per Year

458 Citations

Semantic Scholar estimates that this publication has 458 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Cesaro2011VenoocclusiveDI, title={Veno-occlusive disease in pediatric patients affected by Wilms tumor.}, author={Simone Cesaro and Monica Spiller and M Sartori and Rita D Alaggio and Mattia Peruzzo and Graziella Saggiorato and Gianni Bisogno}, journal={Pediatric blood & cancer}, year={2011}, volume={57 2}, pages={258-61} }